Akèy › Neoplazmi myeloproliferatif › New York › New York City
Etid klinik pou Neoplazmi myeloproliferatif nan New York City, NY
15 etid pou Neoplazmi myeloproliferatif ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Ap rekriteFaz 2
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Ap rekriteFaz 2
- NYP/Weill Cornell Medical Center, New York
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Montefiore, New York
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Ap rekriteFaz 2
- Mount Sinai Hospital, New York
- Memorial Sloan Kettering Cancer Center, New York
Cord Blood Transplant in Adults With Blood Cancers
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- ak 2 plis
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
- Icahn School of Medicine At Mount Sinai, New York
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
- Mount Sinai School of Medicine, New York
- Weill Cornell Medicine, New York
Asciminib Roll-over Study
Ap rekriteFaz 4
- Memorial Sloan Kettering, New York
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
- Icahn School of Medicine At Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Ap rekriteFaz 2
- Memorial Sloan Kettering, New York
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Ap rekriteEtid obsèvasyon
- Memorial Sloan Kettering Cancer Center, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, New York
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Ap rekriteFaz 1
- Columbia University, New York
Etid Neoplazmi myeloproliferatif nan lòt vil
- Houston, TX16 etid
- Boston, MA14 etid
- Milwaukee, WI10 etid
- Miami, FL10 etid
- Durham, NC9 etid
- Baldwin Park, CA9 etid
- Seattle, WA9 etid
- Chicago, IL9 etid
- Portland, OR8 etid
- Cleveland, OH8 etid
- Atlanta, GA8 etid
- Philadelphia, PA8 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.